

Haematologica
HAEMATOL/2015/131144
Version 3

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

Disclosures: Research Funding: SSN - from Celgene; NF - from Celgene and Roche. Honoraria received directly from an entity: LJM - from Celgene and Genentech; SSN - for consulting from Celgene. Advisory Board: NF - from Celgene and Roche. No conflicts of interest: LEF, FBH, DL, CYC, FS.

Contributions: All authors participated in the design of the clinical study, performed the study, collected data, analyzed and interpreted the data, participated in all manuscript drafts and reviews, and approved each stage of the manuscript development.